[go: up one dir, main page]

CL2018000499A1 - Composición que comprende anticuerpos útiles para tratar enfermedades mediadas por interleucina 5 (il-5) y métodos relacionados. - Google Patents

Composición que comprende anticuerpos útiles para tratar enfermedades mediadas por interleucina 5 (il-5) y métodos relacionados.

Info

Publication number
CL2018000499A1
CL2018000499A1 CL2018000499A CL2018000499A CL2018000499A1 CL 2018000499 A1 CL2018000499 A1 CL 2018000499A1 CL 2018000499 A CL2018000499 A CL 2018000499A CL 2018000499 A CL2018000499 A CL 2018000499A CL 2018000499 A1 CL2018000499 A1 CL 2018000499A1
Authority
CL
Chile
Prior art keywords
composition
interleukin
antibodies useful
treating diseases
related methods
Prior art date
Application number
CL2018000499A
Other languages
English (en)
Inventor
Myrna A Monck
Narendra B Bam
Jennifer Dally
Michelle Spatara
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56877084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2018000499(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of CL2018000499A1 publication Critical patent/CL2018000499A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>La presente divulgación se refiere a una composición que comprende anticuerpos útiles para tratar enfermedades mediadas por interleucina 5 (IL-5), tales como asma,  enfermedad pulmonar obstructiva crónica, granulomatosis eosinofílica con poliangitis, síndrome hipereosinofílico, penfigoide bulloso y esofagitis eosinofílica. Además, se divulga el método de producción de la composición y el uso de ella en el tratamiento de enfermedades mediadas por IL-5.</p>
CL2018000499A 2015-08-24 2018-02-23 Composición que comprende anticuerpos útiles para tratar enfermedades mediadas por interleucina 5 (il-5) y métodos relacionados. CL2018000499A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562209000P 2015-08-24 2015-08-24
US201562240131P 2015-10-12 2015-10-12
US201562247906P 2015-10-29 2015-10-29
US201562249497P 2015-11-02 2015-11-02

Publications (1)

Publication Number Publication Date
CL2018000499A1 true CL2018000499A1 (es) 2018-07-06

Family

ID=56877084

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000499A CL2018000499A1 (es) 2015-08-24 2018-02-23 Composición que comprende anticuerpos útiles para tratar enfermedades mediadas por interleucina 5 (il-5) y métodos relacionados.

Country Status (22)

Country Link
US (10) US10870695B2 (es)
EP (2) EP4056590B1 (es)
JP (4) JP6821659B2 (es)
KR (3) KR20180037275A (es)
CN (5) CN108137683A (es)
AU (1) AU2016311385C1 (es)
BR (1) BR112018003741A2 (es)
CA (1) CA2996088A1 (es)
CL (1) CL2018000499A1 (es)
CO (1) CO2018001840A2 (es)
CR (1) CR20180115A (es)
DO (1) DOP2018000057A (es)
EA (1) EA037487B1 (es)
IL (1) IL257539A (es)
MA (1) MA42692A (es)
MX (2) MX2018002319A (es)
PE (1) PE20181176A1 (es)
PH (1) PH12018500379B1 (es)
TW (2) TWI780988B (es)
UY (1) UY36868A (es)
WO (1) WO2017033121A1 (es)
ZA (1) ZA201801158B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11111292B2 (en) 2016-12-23 2021-09-07 Cephalon, Inc. Anti-IL-5 antibodies

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI780988B (zh) 2015-08-24 2022-10-11 英商葛蘭素史密斯克藍智慧財產權有限公司 生藥組成物
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
KR102826635B1 (ko) * 2016-06-17 2025-06-30 제넨테크, 인크. 다중 특이적 항체의 정제
PE20191844A1 (es) * 2017-05-26 2019-12-31 Glaxosmithkline Ip Dev Ltd Composiciones biofarmaceuticas y metodos relacionados
CN119632921A (zh) * 2017-06-06 2025-03-18 葛兰素史克有限责任公司 用于儿科患者的生物药物组合物和方法
TWI801425B (zh) * 2017-09-29 2023-05-11 大陸商江蘇恆瑞醫藥股份有限公司 Il-5 抗體、其抗原結合片段及醫藥用途
WO2019224724A1 (en) * 2018-05-23 2019-11-28 Glaxosmithkline Intellectual Property Development Limited Biopharmaceutical compositions comprising antibody variants
AU2020251627A1 (en) 2019-03-29 2021-11-11 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing antibody against IL-5 and use thereof
US20210008199A1 (en) * 2019-07-10 2021-01-14 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising reduced level of host cell proteins
EP4077388A1 (en) * 2019-12-18 2022-10-26 Tesaro, Inc. Biopharmaceutical compositions and related methods
EP4272756A4 (en) * 2021-02-05 2024-12-11 Bio-Thera Solutions, Ltd. ANTI-IL-5 ANTIBODY FORMULATION, MANUFACTURING METHOD AND USE THEREOF
JP2024527586A (ja) * 2021-07-09 2024-07-25 ヤンセン バイオテツク，インコーポレーテツド 抗－ｔｎｆ抗体組成物を産生するための製造方法
WO2023049803A1 (en) * 2021-09-22 2023-03-30 Sonoma Biotherapeutics, Inc. Il5ra cell surface markers

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07505767A (ja) 1992-02-06 1995-06-29 シェリング・コーポレーション ヒトインターロイキン−５に対するヒト化モノクローナル抗体の設計，クローン化および発現
WO1995014040A1 (en) * 1993-11-19 1995-05-26 Baylor College Of Medicine Monoclonal antibodies specific for human interleukin-5
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US6056957A (en) 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
US5683892A (en) 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
BR9510499B1 (pt) 1994-12-23 2009-05-05 antagonistas de il-5 recombinantes úteis no tratamento de distúrbios mediados por il-5.
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
GB9712410D0 (en) 1997-06-14 1997-08-13 Glaxo Group Ltd Peptides and compounds that bind to the il-5 receptor
JP2008507255A (ja) * 2004-03-12 2008-03-13 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド ヒトｇタンパク質ケモカインレセプター（ｃｃｒ５）ｈｄｇｎｒ１０
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
LT1988910T (lt) 2006-02-28 2018-01-10 Kodiak Sciences Inc. Akriloiloksietilfosforilcholiną turintys polimero konjugatai ir jų gavimo būdas
EP2777710A1 (en) 2007-04-30 2014-09-17 Glaxosmithkline LLC Methods for administering anti-IL-5 antibodies
EP2225275A4 (en) 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
US20110008345A1 (en) * 2007-11-30 2011-01-13 Claire Ashman Antigen-binding constructs
TWI472339B (zh) * 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
CN102026660A (zh) 2008-03-28 2011-04-20 葛兰素史密斯克莱有限责任公司 治疗方法
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
JP5657224B2 (ja) 2009-08-31 2015-01-21 富士フイルム株式会社 放射線画像検出器の撮像面の設置誤差の程度を判定する方法および装置
FR2958646B1 (fr) 2010-04-07 2012-05-18 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
BR112012017071A2 (pt) 2010-01-14 2016-04-12 Univ Nagoya City produto farmacêutico para prevenir ou tratar distúrbios acompanhados da agiogênese ocular e/ou do aumento da permeabilidade vascular ocular
SG192671A1 (en) 2011-02-09 2013-09-30 Glaxosmithkline Llc Lyophilized formulations
EP3058952A1 (en) * 2011-04-07 2016-08-24 Glaxosmithkline LLC Formulations with reduced viscosity
WO2012141978A2 (en) 2011-04-07 2012-10-18 Glaxosmithkline Llc Formulations with reduced viscosity
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
SG11201504260UA (en) * 2013-03-14 2015-10-29 Abbvie Inc Low acidic species compositions and methods for producing and using the same
WO2014141149A1 (en) 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations with reduced viscosity
EP2848615A1 (en) 2013-07-03 2015-03-18 Almirall, S.A. New pyrazole derivatives as CRAC channel modulators
US20160235667A1 (en) 2013-10-02 2016-08-18 Vectura Limited Method and apparatus for making compositions for pulmonary administration
US9738716B2 (en) 2014-01-24 2017-08-22 Ngm Biopharmaceuticals, Inc. Beta klotho binding proteins and methods of use thereof
BR112016018116A2 (pt) 2014-02-06 2018-02-20 Arsanis Biosciences Gmbh anticorpo e sequências específicos para e. coli, preparação farmacêutica ou para diagnóstico compreendendo os mesmos, uso do anticorpo para tratar infecção por e. coli e diagnosticar a doença, ácido nucleico que codifica o anticorpo, um cassete de expressão, plasmídeo ou célula hospedeira compreendendo o mesmo, e método de produção
TW201705961A (zh) 2015-06-11 2017-02-16 阿爾米雷爾有限公司 作為ｊａｋ抑制劑的２－（吡唑并吡啶－３－基）嘧啶衍生物
TWI780988B (zh) 2015-08-24 2022-10-11 英商葛蘭素史密斯克藍智慧財產權有限公司 生藥組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11111292B2 (en) 2016-12-23 2021-09-07 Cephalon, Inc. Anti-IL-5 antibodies

Also Published As

Publication number Publication date
KR20240099511A (ko) 2024-06-28
JP2024123040A (ja) 2024-09-10
US20180251539A1 (en) 2018-09-06
JP2020033351A (ja) 2020-03-05
IL257539A (en) 2018-04-30
US20240294630A1 (en) 2024-09-05
JP7463070B2 (ja) 2024-04-08
CO2018001840A2 (es) 2018-05-31
EA201890572A1 (ru) 2018-10-31
BR112018003741A2 (pt) 2018-09-25
US20240294629A1 (en) 2024-09-05
EA037487B1 (ru) 2021-04-02
TWI750133B (zh) 2021-12-21
PH12018500379A1 (en) 2018-09-03
CN116327923A (zh) 2023-06-27
KR20180037275A (ko) 2018-04-11
JP2022023049A (ja) 2022-02-07
DOP2018000057A (es) 2018-03-15
MA42692A (fr) 2018-07-04
US20200199219A1 (en) 2020-06-25
US20240294628A1 (en) 2024-09-05
CN108137683A (zh) 2018-06-08
TW201722473A (zh) 2017-07-01
US20210340246A1 (en) 2021-11-04
US20220185878A1 (en) 2022-06-16
CN116474091A (zh) 2023-07-25
US12187789B2 (en) 2025-01-07
CN116327921A (zh) 2023-06-27
US20220380452A1 (en) 2022-12-01
US12454571B2 (en) 2025-10-28
US12187790B2 (en) 2025-01-07
US10870695B2 (en) 2020-12-22
PH12018500379B1 (en) 2022-11-23
US20210340247A1 (en) 2021-11-04
US11299541B2 (en) 2022-04-12
NZ739899A (en) 2025-05-02
AU2016311385C1 (en) 2019-08-22
ZA201801158B (en) 2019-08-28
EP4056590A1 (en) 2022-09-14
AU2016311385B2 (en) 2019-05-09
EP3341409A1 (en) 2018-07-04
PE20181176A1 (es) 2018-07-20
EP4056590B1 (en) 2025-10-15
UY36868A (es) 2017-03-31
US20210332125A1 (en) 2021-10-28
CR20180115A (es) 2018-04-12
JP6821659B2 (ja) 2021-01-27
WO2017033121A1 (en) 2017-03-02
US11459384B2 (en) 2022-10-04
AU2016311385A1 (en) 2018-03-15
CN116327922A (zh) 2023-06-27
MX2018002319A (es) 2018-04-11
US11274148B2 (en) 2022-03-15
MX2024001617A (es) 2024-03-06
US12187791B2 (en) 2025-01-07
US11286298B2 (en) 2022-03-29
TW202233238A (zh) 2022-09-01
TWI780988B (zh) 2022-10-11
KR20250086801A (ko) 2025-06-13
CA2996088A1 (en) 2017-03-02
JP2018526369A (ja) 2018-09-13

Similar Documents

Publication Publication Date Title
CL2018000499A1 (es) Composición que comprende anticuerpos útiles para tratar enfermedades mediadas por interleucina 5 (il-5) y métodos relacionados.
CO2019013245A2 (es) Composiciones biofarmacéuticas y métodos relacionados
MX2015009037A (es) Enjuague nasal con miel.
MX2017002765A (es) Il-23a y tnf-alfa orientados y compuesto y sus usos.
UY35350A (es) Pirimidinas condensadas sustituidas con trifluorometilo y su uso
SV2015005019A (es) Anticuerpos anti-il-17a y su uso en el tratamiento de trastornos autoinmunes e inflamatorios
CL2016002088A1 (es) Anticuerpos monoclonales biespecificos contra il-13/il-17; ácido nucleico; célula huésped; método de producción del anticuerpo; inmunoconjugados; formulación farmacéutica; y usos de los anticuerpos biespecíficios para el tratamiento del asma moderada a severa y/o asma eosinofílica.
BR112013023517A2 (pt) &#34;inibidores de produção de leucotrieno, seus usos, e composição farmacêutica&#34;
MX387421B (es) Producción de virus en huevos aviares.
BR112016009365A2 (pt) Método para aumentar, melhorar e estender a produção de etanol e método para diminuir as concentrações finais de dp2 em um produto de fermentação
BR112016010862A8 (pt) formas mórficas de ésteres de hexadeciloxipropil-fosfonato, seu método de preparo e composição compreendendo a dita forma mórfica
MX2016008258A (es) Celulas eucariotas novedosas y metodos para la expresion recombinante de un producto de interes.
MX2016011367A (es) Microorganismo recombinante que expresa analogos de avermectina y uso de los mismos.
MX2019013468A (es) Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab.
BR112015030774A2 (pt) novos compostos para o tratamento de câncer
EA201891805A1 (ru) Способ
MX2018004174A (es) Control biologico de virus vegetales.
UY36034A (es) Derivados de 3,5-diamino-6-cloro-pirazina-2-carboxamida y sales farmaceuticamente aceptables de estos
MX370251B (es) Derivados de difeniloxialquilamina y derivados de ariloxialquilamina, composicion farmaceutica, uso de dicha composicion farmaceutica para tratar, prevenir o inhibir enfermedades inflamatorias pulmonares cronicas y metodo para tratar o prevenir dichas enfermedades.
CN302570931S (zh) 风障叶片（四）
MX376828B (es) Plantas que tienen caracteristicas relacionadas al rendimiento mejoradas y metodos para hacerlas.
CN302188883S (zh) 门铃(5)
BR112017003916A2 (pt) Processo para preparar derivados de 3- fenil/heteroaril-6-fenóxi-8-alquilamino-imidazo [1,2 -b]piridazina
UA97401U (en) Method of metabolic therapy in children with asthma at the background of undifferentiated dysplasia of connective tissue